Boehringer embarks on a PhIII odyssey for a failed Alzheimer's drug — now refocused on schizophrenia with new trial tech and a ‘breakthrough’ at the FDA
In the 8 months since researchers at Boehringer Ingelheim laid claim to a Phase II win for their schizophrenia drug BI 425809, the project team …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
